CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by REVES, J. G.
Right arrow Articles by LEWIS, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by REVES, J. G.
Right arrow Articles by LEWIS, S.

Canadian Journal of Anesthesia, Vol 26, 402-409, Copyright © 1979 by Canadian Anesthesiologists' Society

Midazolam Maleate Induction in Patients with Ischaemic Heart Disease: Haemodynamic Observations

J. G. REVES M.D.1, PAUL N. SAMUELSON M.D.2, and SANDRA LEWIS M.D.2

1 Department of Anaesthesiology, School of Medicine, University of Alabama, Birmingham, Alabama 35294, U.S.A.
2 Department of Anaesthesiology. School of Medicine, University of Alabama, Birmingham, Alabama 35294, U.S.A.

Midazolam maleate is a new water soluble ben-zodiazepine used for induction of anaesthesia. Ten patients with symptomatic ischaemic heart disease were premedicated intramuscularly with morphine 0.1mg·kg-1 and scopolamine 6-8 µg kg-1, 60-90 minutes before induction. The heart rate, systolic/diastolic blood pressure, mean systolic blood pressure, mean pulmonary artery blood pressure, pulmonary artery occluded pressure, mean right atrial pressure, cardiac output (duplicate thermodilution) and arterial blood gas tensions were measured at four time periods: (1) after instrumentation while breathing room air, (2) after transfer to the operating room while breathing 100 per cent oxygen by mask, (3) one to two minutes after intravenous midazolam maleate 0.2mg·kg-1 and (4) four to five minutes after midazolam maleate. The cardiac index, stroke index, heart rate-systolic blood pressure product, systemic vascular resistance index, pulmonary vascular resistance index, left ventricular stroke work index and right ventricular stroke work index were calculated for each of the study time-periods from the measured parameters.

Midazolam maleate anaesthetized all patients and times for induction ranged from 30 to 90 seconds (mean 44). Apnoea occurred in 75 percent of patients and ventilation was assisted in those instances. The PaOO2 was unchanged by midazolam maleate, but the PaCOCO2 rose significantly (p< 0.02) from 5.32 ± 0.19 to 5.85 ± 0.17kPa(46 ± 1.4 to44 ± 1.3 mm Hg) (1-2 min) and 6.1 ± 0.17 kPa (46 ± 1.3 mm Hg) (4-5 minutes after midazolam maleate).

Haemodynamic effects of midazolam maleate were minor and in most cases less than those associated with transfer of the patients to the operating room when the systemic systolic/diastolic blood pressure, mean systemic blood pressure, mean right atrial pressure, pulmonary artery occluded pressure and systemic vascular resistance index all significantly increased (p < 0.01). Midazolam maleate significantly reduced systemic systolic/diastolic pressure, mean systemic blood pressure, stroke volume, left and right ventricular stroke work index and systemic vascular resistance index toward the original resting control.

The heart rate rose from 55 ± 6.6 to 66 ± 5.3 beats per minute (p < 0.01) one to two minutes after midazolam maleate, and the mean right atrial pressure, mean pulmonary artery pressure, pulmonary artery occluded pressure, cardiac index, stroke index, pulmonary vascular resistance index and heart rate-systolic blood pressure product remained unchanged. There were no further significant changes four to five minutes after midazolam maleate, except in systemic systolic/diastolic pressure which continued to decline to the level of the resting control (125/61).

It is concluded that the rapid action of midazolam maleate and its modest effects on haemodynamic parameters, make it a safe and efficacious induction agent in patients with ischaemic heart disease.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by the Canadian Anesthesiologists' Society.